Better Buy: Gilead Sciences vs. Biogen

Investing in blue-chip pharmaceutical stocks can relieve some stress during recessions. For example, shares of Gilead Sciences (NASDAQ: GILD) closed trading Monday up 13.7% year to date, compared with a 5% decline for the broad-market S&P 500 index. Meanwhile, shares of Biogen (NASDAQ: BIIB) have declined by about 6% in 2020, but may rebound sharply due to solid business performance.

With Gilead Sciences marketing a newly authorized treatment for COVID-19 and Biogen developing a novel treatment for Alzheimer's disease, investors' expectations for both stocks are high. But which of the two companies is a better buy today?

Image Source: Getty Images.

Source Fool.com